Navigation Links
TB, HIV and malaria vaccine research gets major boost
Date:5/7/2013

Rockville, MD, US, Oxford, UK and Basel, Switzerland 7 May 2013 Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

The grant, provided by the Bill & Melinda Gates Foundation, allows the three groups to work together to develop scalable methods to enable large-scale production of multiple novel chimpanzee adenovirus vector constructs.

"We are pleased to expand our partnership with Okairos focusing on novel constructs utilizing chimpanzee adenovirus for next generation TB vaccines, as well as our collaboration with the University of Oxford, both of which are central to our organizational mission," said Tom Evans, MD, Interim CEO of Aeras. "This effort to improve optimization and scale up under current good manufacturing practices could also potentially benefit our peers in HIV and malaria vaccine development."

Novel constructs to be pursued include Okairos' proprietary technology platform that uses potent chimpanzee adenovirus vectors to stimulate robust T-cell and antibody responses against selected antigens.

Dr Riccardo Cortese, Chief Executive Officer of Okairos, said: "This new collaboration will enable us to advance our promising technology platform. By continuing to work with Aeras and Oxford, partners with proven expertise in vaccines development, we ultimately aim to deliver novel vaccines to developing countries where there is great need."

Aeras and Oxford both bring to the collaboration considerable expertise in vaccine development and manufacturing, with Oxford currently developing multiple vaccines, including vaccines against HIV, malaria and TB in clinical trials in the UK and Africa, and Aeras focusing primarily on tuberculosis vaccine research and development.

"Chimpanzee adenovirus-based vaccines have recently been shown to safely induce exceptionally potent cellular immunity in adults, children and infants, and are in clinical trials involving over 1,000 vaccinees in seven countries," commented Adrian Hill, Director of the Jenner Institute at Oxford University. "The diseases targeted, including malaria, HIV/AIDS and tuberculosis, are the greatest infectious killers of our time so this investment in manufacturing technology is very timely."


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
240-599-3018
Aeras
Source:Eurekalert

Related medicine news :

1. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
2. New process would make anti-malarial drug less costly
3. UCI researchers create mosquitoes incapable of transmitting malaria
4. The math of malaria
5. Novel anti-malarial drug target identified
6. New research reveals extent of poor-quality antimalarial medicines in South American countries
7. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
8. Novel technique demonstrates interactions between malaria parasite and HIV
9. Meddling with male malaria mosquito mating plug to control an epidemic
10. Protein impedes microcirculation of malaria-infected red blood cells
11. New opportunity for rapid treatment of malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead ... is the creation of published author Laura Weigel Douglas, an avid reader who lives ... a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known ... ability to sell luxury homes anywhere on the planet. The luxury home market is ... Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten ...
(Date:5/24/2017)... ... ... thinking of a visit to San Francisco , fall is a great time to ... , Business Architecture Associates is pleased to offer 5 days of training courses, available to ... for individuals, and as 4-½ day corporate package for up to 3 employees with the ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research Inc. ... been awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery ... the Canadian Commercial Corporation (CCC) ( Ottawa, ... Systems to administer general anesthesia to patients requiring ... "The US Marine Corps have been a ...
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
Breaking Medicine Technology: